Atlas Trials

A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

Clinical trial NCT01830985 · COMPLETED

Trial details

NCT number
NCT01830985
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Rheumatoid Arthritis
Start date
2013-04-01
Primary completion
2014-07-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.